ACADIA Pharmaceuticals Inc. (LON:0A4W)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 2.75B +49.2% |
| Revenue (ttm) | 829.44M +9.9% |
| Net Income | 284.48M +64.1% |
| EPS | 1.66 +60.4% |
| Shares Out | n/a |
| PE Ratio | 9.68 |
| Forward PE | 40.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 101 |
| Average Volume | 1,809 |
| Open | 26.87 |
| Previous Close | 18.62 |
| Day's Range | 26.87 - 26.87 |
| 52-Week Range | 16.31 - 26.87 |
| Beta | n/a |
| RSI | 85.57 |
| Earnings Date | May 6, 2026 |
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting sy... [Read more]
Financial Performance
In 2025, ACADIA Pharmaceuticals's revenue was $1.07 billion, an increase of 11.87% compared to the previous year's $957.80 million. Earnings were $391.00 million, an increase of 72.66%.
Financial numbers in USD Financial StatementsNews
ACADIA Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
Management outlined commercial and pipeline progress, including ambitious sales targets for key brands, innovative product launches, and a robust late-stage pipeline. Clinical updates highlighted upcoming data for Alzheimer's and depression programs, with a focus on unmet needs and regulatory strategy.
Acadia Pharmaceuticals price target lowered to $32 from $33 at Citi
Citi lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $32 from $33 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals reports Q1 EPS 2c, consensus 8c
Reports Q1 revenue $268M, consensus $280.27M. “Acadia delivered a solid first quarter of 2026 with total revenues of $268 million, driven by a strong start from DAYBUE, which generated sales…
Acadia Pharmaceuticals backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B
16:12 EDT Acadia Pharmaceuticals (ACAD) backs FY26 revenue view $1.22B-$1.28B, consensus $1.25B
ACADIA Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 11% year-over-year to $268M, led by DAYBUE's 20% and NUPLAZID's 6% growth. DAYBUE STIX launched with strong uptake, and guidance for both brands was reaffirmed. Key pipeline catalysts include phase II remlifanserin data in ADP expected in August–October.
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2026. “Acadia delivered a solid first quarter of 202...
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D.
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the planned retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development. Dr. Thompson has deci...
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at two upcoming investor conferences: BofA Securities 2026 Health Care Conference Firesi...
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present multiple original data presentations spanning its portfolio at the 2026 American Academy of ...
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter 2026 financial results on Wednesday, May 6, 2026, after the close of the U.S. f...
Acadia Pharmaceuticals price target lowered to $29 from $30 at RBC Capital
RBC Capital lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $30 and keeps an Outperform rating on the shares as part of the firm’s broader research…
Acadia Pharmaceuticals announces Daybue Stix available in U.S.
Acadia Pharmaceuticals (ACAD) announced Daybue Stix is now broadly available in the United States for the treatment of Rett syndrome in adults and pediatric patients two years of age and…
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced DAYBUE® STIX (trofinetide) for oral solution, a dye- and preservative-free powder formulation of trofinetide, is ...
Acadia Pharmaceuticals upgraded to Buy at BofA following 25% pullback
As previously reported, BofA analyst Tazeen Ahmad upgraded Acadia Pharmaceuticals (ACAD) to Buy from Neutral with an unchanged price target of $29. The recent 25% pullback in share price is…
Acadia Pharmaceuticals upgraded to Buy from Neutral at BofA
BofA upgraded Acadia Pharmaceuticals (ACAD) to Buy from Neutral with a $29 price target
ACADIA Pharmaceuticals Transcript: Stifel 2026 Virtual CNS Forum
Remlifanserin is advancing in robustly designed trials for Alzheimer's and Lewy body dementia psychosis, with a focus on improved efficacy, safety, and regulatory alignment. The phase II readout is expected between August and October, while a novel R-ketamine asset is progressing in MDD.
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on Tuesday, March 17, 2026 at 8:...
ACADIA Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026
Strong commercial growth and robust financials support ongoing investment in a diverse pipeline, with key catalysts including the remlifanserin phase II readout and new DAYBUE formulation. Expansion efforts target both US and international markets, despite regulatory challenges.
Acadia Pharmaceuticals price target raised to $34 from $31 at JPMorgan
JPMorgan raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $34 from $31 and keeps an Overweight rating on the shares. The firm updated the company’s model post the…
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Mr. Poole will serve on ...
Acadia Pharmaceuticals price target lowered to $29 from $31 at BofA
BofA lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $29 from $31 and keeps a Neutral rating on the shares. The firm maintains its FY26 Daybue sales estimate…
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) informed th...
ACADIA Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Management projects $1.7B in 2028 sales, driven by NUPLAZID and DAYBUE, with new formulations and expanded field force fueling growth. Remlifanserin phase II data is expected by fall, and regulatory reexamination for DAYBUE in Europe will include patient advocacy.
Acadia Pharmaceuticals price target lowered to $33 from $36 at Citi
Citi lowered the firm’s price target on Acadia Pharmaceuticals (ACAD) to $33 from $36 and keeps a Buy rating on the shares.
Acadia Pharmaceuticals price target raised to $37 from $35 at TD Cowen
TD Cowen analyst Ritu Baral raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $35 and keeps a Buy rating on the shares. The firm said in…